Amgen (AMGN) Q1 'Disappointing' - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Amgen (AMGN) Has the Best Pipeline in Biotech, Piper Jaffray Says
April 25, 2014 7:38 AM EDTPiper Jaffray analyst Joshua E. Schimmer, MD reiterated an Overweight rating and $143 price target on Amgen (NASDAQ: AMGN) Friday saying a deep dive analysis into AMGN's migraine program suggests they are likely to... More
Amgen, Inc. (AMGN) Misses Q1 EPS by 7c
April 22, 2014 4:48 PM EDTAmgen, Inc. (NASDAQ: AMGN) reported Q1 EPS of $1.87, $0.07 worse than the analyst estimate of $1.94. Revenue for the quarter came in at $4.52 billion versus the consensus estimate of $4.76 billion.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
... More